MM-MSCs protect MM cells from chemotherapy-induced apoptosis via activation of NF-κB and its downstream pathways [66].In addition, MSCs-EVs isolated from chronic lymphocytic leukemia (CLL) patients (CLL-MSCs-EVs) could additionally protect CLL B cells from spontaneous and drug-induced apoptosis in a dose-dependent manner, enhancing their survival and tumor progression through pathways related to activation of B-cells receptors [67]. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.